Liraglutide
Also known as Liraglutide · Victoza · Saxenda · GLP-1 analog
New
Reconstitution & dosing guide
5 mg · 10 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
Liraglutide (LGE10) · Not in current stock
$85 / vial
5mg x 10 vials
Liraglutide (LGE5) · Not in current stock
$50 / vial
Prices per vial · Research use only · Not medical advice.
Once-daily GLP-1 receptor agonist peptide with FDA-approved branded products for type 2 diabetes and chronic weight management; research vials are not those products.
How to picture it
An earlier long-acting GLP-1 receptor agonist — same core "fed message" story as semaglutide: reduce appetite noise, steady glucose handling, slow meal transit. Picture the gut's post-meal broadcast extended across the day, with a long track record of study in diabetes and weight research. Foundational molecule in the class, different dosing/kinetics history.
Research focus & benefits
- GLP-1 receptor clinical literature
- Appetite and glycemic pathway studies
- Foundational incretin drug-class research
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Liraglutide is a fatty-acid-acylated GLP-1 analog with ~13-hour half-life enabling daily dosing. Brand products (Victoza, Saxenda) are approved medicines. Research-catalog material is a separate, unregulated supply channel and must not be treated as pharmaceutical equivalent.
Mechanism
GLP-1 receptor agonism: enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral pathways.
Research uses
- Type 2 diabetes outcomes trials (pharma)
- Obesity / weight-management trials (Saxenda SCALE program)
- Cardiovascular outcome studies for branded liraglutide
Research dosing notes
Approved products use carefully titrated daily mcg doses. Research vials are not pen devices. Never substitute research material for prescribed medication.
Half-life / kinetics
~13 hours (acylated analog)
Common research routes
Reported considerations
- Nausea, vomiting, GI effects
- Gallbladder events
- Rare pancreatitis signal
- Thyroid C-cell warnings (rodent; boxed warning class)
Contraindications / cautions
- Personal/family MTC or MEN2
- Pregnancy
- History of pancreatitis — medical decision
Common research stacks
- Generally studied as monotherapy in medical settings
Legal / access note
FDA-approved branded products exist. Research peptides are not approved drugs and are not interchangeable with Victoza/Saxenda.